Pfizer Reports Strong Q2 2026 Results and Signals Strategic Expansion
After recording an impressive jump in profits above forecasts, the company is preparing for a dramatic change and is signaling a mega-acquisition to enter one of the most profitable markets in the pharma world with force.
Pharmaceutical giant Pfizer released its financial results for the second quarter of 2026, showing performance that exceeded market forecasts. The company reported adjusted earnings of 77 cents per share, above analyst expectations of 68 cents per share, while simultaneously raising its annual revenue guidance to a range of $60.5 billion to $62.5 billion.
One of the key strengths in the reports was the blood thinner Eliquis, whose sales jumped by 19% and totaled approximately $2.43 billion during the quarter. This is a significantly higher result than previous forecasts, with Pfizer attributing the increase to stable global demand and favorable pricing conditions in the US market.
Alongside the positive results, the company continues to deal with a sharp decline in revenue from COVID-19 products. In this context, Pfizer announced an additional efficiency program of $2.5 billion, which will be implemented between 2027 and 2029, adding to the efficiency measures already being implemented at the company.
At the same time, Pfizer continues to focus its growth strategy on acquisitions and expanding its product portfolio. The company reported that revenue from products added through acquisitions rose by 25%, and the market continues to monitor the move to acquire the company Metsera in a deal estimated at approximately $10 billion. If completed, the deal is expected to strengthen Pfizer's position in the weight-loss drug market, which is currently considered one of the most prominent growth engines in the pharmaceutical industry.
Despite the encouraging reports, Pfizer estimates that more significant growth is expected only after 2028. The company continues to deal with the decline in demand for COVID-19 products and the expiration of patents on some of its flagship drugs, and is building future growth engines through the development of new drugs and strategic acquisitions, with the goal of maintaining its position as one of the largest pharmaceutical companies in the world.
